Report Categories
View AllRecent Articles
View All
What Neumora Therapeutics NMRA disclosed about crisis preparedness NMRA Neumora Therapeutics Q4 2025 Earnings EPS Miss Zero Revenue
Is Dole DOLE stock continuing its trend Dole posts 84 percent EPS beat exceeding analyst estimates
Fox FOXF delivers massive earnings beat with 115 EPS surprise shares rise 2 on revenue growth
COSO CoastalSouth posts 83 percent Q1 2026 EPS miss but shares edge higher in todays trading